New research study investigating a treatment for Idiopathic Generalized Epilepsy

If you still experience seizures despite taking medications, there is a new epilepsy clinical study available for individuals 12 years and older with hard-to-treat idiopathic generalized epilepsy (also called primary generalized epilepsy).

Find out if you could be eligible for the NAUTILUS Study.

Take the Quiz

Doctor looking happily at a patient with a paint brush and palette

About IGE Epilepsy | NAUTILUS Study | The RNS® System | FAQ

What is Idiopathic Generalized Epilepsy (IGE)?

Individuals with idiopathic generalized epilepsy can experience generalized tonic clonic seizures (also known as convulsions or grand mal seizures), myoclonic seizures, and absence seizures.

Idiopathic means that your doctor cannot find anything in your brain that is causing your seizures. Generalized epilepsy is when seizures affect both sides of your brain at the same time.

SEE IF YOU COULD BE ELIGIBLE FOR A CLINICAL STUDY TO TREAT IGE

About the NAUTILUS Study

graphic of brain with stylized brainwave

The NAUTILUS research study is evaluating the safety and effectiveness of thalamic stimulation with the NeuroPace RNS System as an additional treatment in reducing the frequency of primary generalized seizures in people 12 years and older with drug-resistant idiopathic generalized epilepsy.

Specifically, this study will involve participants with IGE whose seizures have not been controlled by antiseizure medications and who currently have generalized tonic clonic seizures, with or without myoclonic or absence seizures.

lf you have been diagnosed with IGE and still have seizures after trying 2 or more anti-seizure medications, you may be eligible for the NAUTILUS Study.

Take the Quiz

CAUTION—Investigational device. Limited by United States law to investigational use for the following Indications for Use: The RNS® System is intended for thalamic stimulation as an adjunctive therapy for the treatment of primary generalized seizures in individuals 12 years of age or older who have drug-resistant idiopathic generalized epilepsy.

If your current epilepsy treatment is not working, a clinical study of neurostimulation for drug-resistant IGE may be an option

What is Drug-Resistant Epilepsy?

If you have tried at least two anti-seizure medications and still experience seizures, you may have drug-resistant epilepsy. Doctors may also refer to this type of epilepsy as refractory, intractable, hard-to-treat, or uncontrolled seizures.

30% of people with epilepsy still experience uncontrolled seizures despite taking anti-seizure medicine. lf your current epilepsy treatment is not working, you are not alone. A clinical study investigating responsive neurostimulation to treat drug-resistant idiopathic generalized epilepsy may be an option.

graphic of three pills
RNS product image

What is the RNS System?

The RNS System is a medical device that is FDA approved for the treatment of drug-resistant focal epilepsy (also called partial onset epilepsy). The RNS System consists of an implantable neurostimulator and small wires (called leads). In the NAUTILUS study, one lead will be placed in the left side of the brain within an area called the centromedian nucleus of the thalamus, and the other lead will be placed in the right centromedian nucleus of the thalamus. Once placed, the device is designed to be unnoticed by others.

How Does the RNS System Work?

  • It monitors brain activity continuously
  • It is programmed to recognize and respond to your brain patterns, sending brief stimulation to help prevent seizures before they start.
  • It records and reports your EEG information for your doctor to review.
How the RNS System Works
swipe left or right

Ready to see if you may be eligible?

Take the Quiz

Drawing of hand checking off boxes on a checklist

FAQs

Why is this study being done?

The RNS System is already approved by the FDA to treat some types of focal epilepsy, but it has not been approved for other types of epilepsy. The purpose of the NAUTILUS Study is to see if the RNS System is safe and effective (works well) as an additional treatment in reducing the frequency of primary generalized seizures in individuals 12 years and older who have drug-resistant idiopathic generalized epilepsy.

How long will I be in this study?

You will be in the NAUTILUS Study for 2 years after you are implanted with the RNS System.

What are my responsibilities if I take part in this study?

If you are enrolled in the NAUTILUS Study, you will be asked to do the following:

  • Enter your seizure information in an electronic diary every day.
  • Attend all study visits (3-4 times per year) for 2 years and complete all study activities. The first year the study doctor will see you in-person for appointments, and in the second year, some of your visits may be done in-person, by telehealth or by telephone.
  • Tell the study team about any side effects, illnesses and injuries (including hospitalizations) you have while you are in the study.
  • Use the NeuroPace Remote Monitor as instructed to send information from your device to your doctor.
Share Tweet Share Pin
Share Tweet Share Pin

This site uses cookies to store information on your computer. Some are essential to make our site work; others help us improve the user experience. By using the site, you consent to the placement of these cookies. You may at any time change the settings regarding cookies. Read our privacy statement to learn more. Do not sell my personal information.

X
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
JSESSIONIDsessionThe JSESSIONID cookie is used by New Relic to store a session identifier so that New Relic can monitor session counts for an application.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
s_ccsessionThis cookie is set by Adobe Analytics to determine if cookies are enabled or not.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
CookieDurationDescription
ac_enable_tracking1 monthThis cookie is set by Active Campaign to denote that traffic is enabled for the website.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_UA-55828317-31 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
demdex5 months 27 daysThe demdex cookie, set under the domain demdex.net, is used by Adobe Audience Manager to help identify a unique visitor across domains.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
CookieDurationDescription
_fbp3 monthsThis cookie is set by Facebook to display advertisements when either on Facebook or on a digital platform powered by Facebook advertising, after visiting the website.
fr3 monthsFacebook sets this cookie to show relevant advertisements to users by tracking user behaviour across the web, on sites that have Facebook pixel or Facebook social plugin.
VISITOR_INFO1_LIVE5 months 27 daysA cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSCsessionYSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devicesneverYouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-idneverYouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
CookieDurationDescription
AMCV_98CF678254E93B1B0A4C98A5AdobeOrg2 yearsNo description
AMCVS_98CF678254E93B1B0A4C98A5AdobeOrgsessionNo description
DrupalVisitorMobilesessionNo description available.
FASRVsessionNo description available.
FORMASSEMBLYsessionNo description available.
prism_7986813311 monthNo description
SAVE & ACCEPT
Powered by CookieYes Logo
Thanks for your interest in the NAUTILUS Study, which is to find out whether the NeuroPace RNS® System is safe and effective (works well) as an additional treatment for drug-resistant, idiopathic generalized epilepsy in individuals 12 years of age and older.

There are specific criteria to enroll in this study and your answers to this quiz will let NeuroPace know whether you might meet these criteria. 
Are you answering this Quiz as a parent or guardian of a teen at least 12 years of age?
Note that throughout, “you” may pertain directly to you, or to an individual under 18 for whom you have legal authority to provide the information. If so, you (or your parent or guardian if under 18 years of age) will be contacted by a study representative who will ask some additional questions and answer any questions you have. 








How old are you?
Have you been diagnosed with epilepsy?
Do you experience primary generalized seizures including tonic clonic seizures with or without myoclonic or absence seizures?
How many anti-seizure medications have you tried?
Do you have idiopathic generalized epilepsy?
Idiopathic generalized epilepsy means that there is no known cause, or that the cause is thought to be genetic, and seizures start on both sides of the brain all at once. Sometimes this is called primary generalized epilepsy. 
Based on these responses, you may be a candidate for the Nautilus Study.  Are you interested in being contacted to learn more about the Nautilus Study?
Enter your information to learn more about the Nautilus Study. If answering on behalf of your teen, please enter your own information. 





By clicking ‘FINISH QUIZ’, you are agreeing to the terms of our Privacy Policy. You also acknowledge and agree to receiving communications from NeuroPace through the contact information you have provided above. You can unsubscribe at any time.
Unfortunately, it appears the potential study participant is not an appropriate candidate for the Nautilus Study.
The study is evaluating the safety and effectiveness of the NeuroPace RNS® System as an additional treatment for drug-resistant, idiopathic generalized epilepsy in individuals 12 years of age and older. We suggest you discuss potential treatment options with your physician.
You appear to be a potential Nautilus Study participant. 
Unfortunately, since you are a minor, we cannot ask you for your contact information without permission from your parents or guardian.

Please click "FINISH QUIZ" then have your parent or legal guardian complete a new quiz.



Step 1 of 7

14%
    The RNS System is for individuals 18 and older who have focal epilepsy and have tried two or more medications without finding seizure control.
  • Based on your answers, your patient might benefit from the RNS System.

    Get your profile and a list of questions to ask your doctor.

  • Unfortunately it appears your patient is not an appropriate candidate for the RNS® System at this time.

  • The RNS® System is intended for patients who have undergone diagnostic testing that localized no more than 2 epileptogenic foci.

    If your patient has not undergone diagnostic testing, search here to find a comprehensive epilepsy center that can evaluate your patient, including determining if the RNS System is right for them.

  • If you are interested in learning more about the RNS® System, you can have an RNS® System professional contact you by filling out the form below:

  • By filling out this form, you are agreeing to the terms of our privacy policy. This form is intended for US residents only.

    By clicking submit, you are agreeing to receive communications from NeuroPace. You can unsubscribe at any time.

    * Required fileds

Share your Story: Terms and conditions

By filling out the form and submitting your story (and/or photograph), you are agreeing to the following:

  1. NeuroPace may review the information and any photographs you provide for potential publication on our website.
  2. If NeuroPace decides to use your story, we will contact you and ask you to sign a release for a version of your story to be used on the NeuroPace website, Facebook, Instagram, Twitter and/or LinkedIn. Unless you sign the release, we will not publish the story, your name, or the photographs you provided.
  3. Regardless of whether we publish your story, we will add your name and e-mail address to the NeuroPace email list to hear from us about product updates, upcoming events and other relevant information. We will not sell your information to third parties. 
  4. Our use of your information is subject to our Privacy Policy, which you can access here.
neuropace logo
  • Patients
  • Providers
  • Corporate
  • PDMS
  • nSight
  • Take the Quiz